A critical overview of the pharmacologic management of treatment-resistant depression

被引：43

作者：

Nierenberg, Andrew A. ^{[1
]}

Katz, Judith ^{[1
]}

Fava, Maurizio ^{[1
]}

机构：

[1] Massachusetts Gen Hosp, Depress Clin & Res Program, Boston, MA 02114 USA

来源：

PSYCHIATRIC CLINICS OF NORTH AMERICA | 2007年 / 30卷 / 01期

关键词：

D O I：

10.1016/j.psc.2007.01.001

中图分类号：

R749 [精神病学];

学科分类号：

100205 ;

摘要：

Major depressive disorder is a frequent, serious disorder that usually responds partially to treatment and leaves many patients with treatment resistance. This article reviews and critically evaluates the evidence for the management of treatment-resistant depression and examines pharmacologic approaches to alleviate the suffering of patients who benefit insufficiently from initial treatment.

引用

页码：13 / +

页数：18

共 140 条

[1] Preliminary experience with adjunctive quetiapine in patients receiving selective serotonin reuptake inhibitors [J].

Adson, DE ;

Kushner, MG ;

Eiben, MK ;

Schulz, SC .

DEPRESSION AND ANXIETY, 2004, 19 (02) :121-126

[2] Algorithm-based treatment of major depression in an outpatient clinic: clinical correlates of response to a specific serotonin reuptake inhibitor and to triiodothyronine augmentation [J].

Agid, O ;

Lerer, B .

INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2003, 6 (01) :41-49

[3] Attention deficit hyperactivity disorder in childhood among adults with major depression [J].

Alpert, JE ;

Maddocks, A ;

Nierenberg, AA ;

OSullivan, R ;

Pava, JA ;

Worthington, JJ ;

Biederman, J ;

Rosenbaum, JF ;

Fava, M .

PSYCHIATRY RESEARCH, 1996, 62 (03) :213-219

[4] S-adenosyl-L-methionine (SAMe) as an adjunct for resistant major depressive disorder -: An open trial following partial or nonresponse to selective serotonin reuptake inhibitors or venlafaxine [J].

Alpert, JE ;

Papakostas, G ;

Mischoulon, D ;

Worthington, JJ ;

Petersen, T ;

Mahal, Y ;

Burns, A ;

Bottiglieri, T ;

Nierenberg, AA ;

Fava, M .

JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2004, 24 (06) :661-664

[5]

Alpert Jonathan E, 2002, Ann Clin Psychiatry, V14, P33, DOI 10.1023/A:1015271927517

[6]

Andersen B, 1990, J AFFECT DISORDERS, V18, P289

[7]

ANDERSON IM, 1986, PSYCHOPHARMACOLOGY, V89, P131

[8] Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability [J].

Anderson, IM .

JOURNAL OF AFFECTIVE DISORDERS, 2000, 58 (01) :19-36

[9] Patients with severe depression may benefit from buspirone augmentation of selective serotonin reuptake inhibitors:: Results from a placebo-controlled, randomized, double-blind, placebo wash-in study [J].

Appelberg, BG ;

Syvälahti, EK ;

Koskinen, TE ;

Mehtonen, OP ;

Muhonen, TT ;

Naukkarinen, HH .

JOURNAL OF CLINICAL PSYCHIATRY, 2001, 62 (06) :448-452

[10] Triiodothyronine augmentation in the treatment of refractory depression - A meta-analysis [J].

Aronson, R ;

Offman, HJ ;

Joffe, RT ;

Naylor, CD .

ARCHIVES OF GENERAL PSYCHIATRY, 1996, 53 (09) :842-848

← 1 2 3 4 5 6 7 8 9 10 →